Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide

Nat Med. 2004 Oct;10(10):1128-32. doi: 10.1038/nm1111. Epub 2004 Sep 26.


The JNK pathway is known to be activated in several tissues in the diabetic state, and is possibly involved in the development of insulin resistance and suppression of insulin biosynthesis. Here we show a potential new therapy for diabetes using cell-permeable JNK-inhibitory peptide. Intraperitoneal administration of the peptide led to its transduction into various tissues in vivo, and this treatment markedly improved insulin resistance and ameliorated glucose tolerance in diabetic mice. These data indicate that the JNK pathway is critically involved in diabetes and that the cell-permeable JNK-inhibitory peptide may have promise as a new therapeutic agent for diabetes.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Blotting, Western
  • Diabetes Mellitus, Type 2 / therapy*
  • Fluorescein-5-isothiocyanate
  • Genetic Therapy*
  • Immunoprecipitation
  • Injections, Intraperitoneal
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mitogen-Activated Protein Kinase 8 / antagonists & inhibitors*
  • Molecular Sequence Data
  • Peptides / administration & dosage
  • Peptides / pharmacology
  • Peptides / therapeutic use*
  • Transfection


  • Peptides
  • Mitogen-Activated Protein Kinase 8
  • Fluorescein-5-isothiocyanate